Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2012
  • Online publication date: September 2012

Section 4 - Summary and Conclusions

References

[1] BeanWB (editor). Sir William Osler: Aphorisms from his Bedside Teachings and Writings. Collected by Robert Bennett Bean. New York: Schuman; 1950.
[2] CaldwellJA. Go pills in combat: prejudice, propriety, and practicality. Air & Space Power J. 2008; 22(3): AFRP 97–104.
[3] Department of Defense. Human Factors Analysis and Classification System: A Mishap Investigation and Data Analysis Tool. Jan 11 2005. http://hfacs.com/about-hfacs-framework. (Accessed Dec 20 2010).
[4] RasmussenN. Speed and total war. In: On Speed: The Many Lives of Amphetamines. New York: New York University Press; 2008: 53–85.
[5] CornumR, CaldwellJ, CornumK. Stimulant use in extended flight operations. Airpower Journal 1997; 11(1): 53–8.
[6] EmondsonDL, VanderbeekRD. The use of amphetamines in U.S. air force tactical operations during desert shield & storm. Aviat Space Environ Med 1995; 66: 260–3.
[7] Unpublished report, Desert Shield/Desert Storm – Aerospace Medicine Consolidated After-Action Report: USAF summary of 29 individual after-action reports. Proceedings of the Squadron Medical Element (SME) After-Action Conference, at Langley AFB, VA, May 20–22 1991.
[8] Boston Globe January 4, 2003. Defense Cites Stimulants in “Friendly Fire” Case. http://www.globalsecurity.org/org/news/2003/030104-speed01.htm. (Accessed Sept 4 2010).
[9] BellandKM, BissellC. A Subjective study of fatigue during navy flight operations over Southern Iraq: Operation Southern Watch. Aviat Space Environ Med 1994; 65: 557–61.
[10] BahjatA. Can one carrier take the place of two? Navy Times Sept 1 1997: 22.
[11] Dept. of the Navy, Naval Strike Air Warfare Center (NSAWC)/Naval Operational Medicine Institute (NOMI)/Naval Aeromedical Research Labs (NAMRL) joint document, NAVMED P-6410: Performance Maintenance During Continuous Flight Operations: A Guide for Flight Surgeons. Jan 1 2000.
[12] ChhiengN. Max Hours in Sheik Isa, the Go Pill Experience. Approach: The Navy & Marine Corps Aviation Safety Magazine Sept 2003; 8–10: p. 8.
[13] WayH. Operational Implementation of a Performance Maintenance Program. CONTACT: The Newsletter of the Society of US Naval Flight Surgeons. Jan 2006; 30(1).
[14] PerryM, ReeveS. Unpublished report. Carrier Air Wing Performance Maintenance Program After-Action Report. Dec 2009.
[15] KenagyDN, BirdCT, WebberCM, FischerJR. Dextroamphetamine use during B-2 combat missions. Aviat Space Environ Med 2004; 75: 381–6.
[16] Operation Iraqi Freedom. http://www.globalsecurity.org/military/ops/iraqi_freedom.htm (Accessed Jul 30 2010).
[17] LeDucPA, RileyD, HoffmanSM, BrockME, NormanD. The effects of sleep deprivation on spatial disorientation. US Army Aeromed Research Lab. Ft. Rucker, AL Dec 1999. Report No. 2000–09.
[18] DarlingtonK, PalacioLV, DowlerT, LeDucP. Situational awareness, crew resource management and operational performance in fatigued two-man crews using three stimulant countermeasures. US Army Aeromed Research Lab. Ft. Rucker, AL. Nov 2006.
[19] CrowleyJS. Human factors of night vision devices: anecdotes from the field concerning visual illusions and other effects. US Army Aeromed Research Lab. Ft. Rucker, AL. May 1991. Report No. 91–15.
[20] WheelerD, editor. Warfighter Endurance Management During Continuous Flight and Ground Operations. Brooks Air Force Base, TX: United States Air Force School of Aerospace Medicine; 2002.
[21] MeadowsAB. Fatigue in Continuous and Sustained Airpower Operations: Review of Pharmacological Countermeasures and Policy Recommendations. Air Command and Staff College, Air University. Maxwell Air Force Base, AL. March 2005.
[22] CaldwellJA, GilreathSR. A survey of aircrew fatigue in a sample of U.S. Army aviation personnel. Aviat Space Environ Med 2002; 73: 472–80.
[23] DavenportN. Unpublished data, Naval Safety Center, Norfolk, VA; 2010.
[24] Air and Space Interoperability Council. Fatigue Countermeasures in Sustained and Continuous Operations. Advisory Publication ACS (ASMG) 6000 (Proposed). Jul 8 2010.
[25] JaegerHF. A glance at the tip of the iceberg: commentary on “recommendations for the ethical use of pharmacological fatigue countermeasures in the U.S. military.”Aviat Space Environ Med 2007; 78(5 Suppl): B128–30.
[26] MeijerM. A human performance perspective on the ethical use of cogniceuticals: commentary on “recommendations for the ethical use of pharmacological fatigue countermeasures in the U.S. military.”Aviat Space Environ Med 2007; 78(5): B131–3.
[27] NielsonJN. Danish perspective: commentary on “recommendations for the ethical use of pharmacological fatigue countermeasures in the U.S. military.”Aviat Space Environ Med 2007; 78(5 Suppl): B134–5.
[28] RoedigE. German perspective: commentary. Aviat Space Environ Med 2007; 78(5): B136–7.
[29] Title 10 U.S.C 1107. (Military medical care) “Notice of use of an investigational new drug or a drug unapproved for its applied use.”
[30] DoD Instruction 6200.02. Application of Food and Drug Administration (FDA) Rules to Department of Defense Force Health Protection Programs http://www.dtic.mil/whs/directives/corres/pdf/620002p.pdf. (Accessed Sep 4 2010).
[31] DoD Instruction 6200.02, encl. 2, p 6, para. E2.2.
[32] Dept of the Air Force, HQ Washington DC. Updated Modafinil Policy for Management of Fatigue Among Aircrews and Special Operational Duty Personnel (HQ USAF/SG and HQ USAF/XO Joint Memo, “Modafinil and Management of Aircrew Fatigue,” Aug 31 2006.
[33] Dept of the Air Force, HQ Washington DC. Policy Letter on the Implementation of HQ USAF/XO Message, Combat Air Force (CAF) Aircrew Fatigue Countermeasures. Jun 26 2001.
[34] Dept of the Air Force, HQ AF Special Operations Command. Memorandum: Air Force Special Operations Command Ground Combat Personnel Fatigue Countermeasures. Feb 5 2009.
[35] CaldwellJA, CaldwellJL, SmytheNK, HallKK. A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining alertness and performance of aviators: a helicopter simulator study. Psychopharmacology (Berl) 2000; 150: 272–82.
[36] CaldwellJA, CaldwellJL. Fatigue in military aviation: an overview of U.S. military-approved pharmacological countermeasures. Aviat Space Environ Med 2005; 76(7 Suppl): C39–51.
[37] EismanD. Navy to Tighten Control of Pills. Norfolk Virginian-Pilot Jan 27 2003.
[38] Dept of the Army, US Army Aeromedical Research Laboratory (USAARL)/US Army Safety Center (USASC) Joint Document. Leader’s Guide to Crew Endurance. Aug 1997.
[39] Army Aeromedical Policy Letter. Medications: Pre-Deployment Rest or Sustained Operations Agents. (Medication Class 2A) USAARL. Feb 2003. https://aamaweb.usaama.rucker.amedd.army.mil/aamaweb/policyltrs/Predeployment_Feb2003.pdf (Accessed 20 Aug. 2010).
[40] Personal communication with Director, US Army Aeromedical Activity, Jul 2010.
[41] GoreRK, WebbTS, HermesEDA. Fatigue and stimulant use in military fighter aircrew during combat operations. Aviat Space Environ Med 2010; 81: 719–27.
[42] BonnetMH, BalkinTJ, DingesDF, et al. AASM Task Force Report: use of stimulants to modify performance during sleep loss: a review by the Sleep and Stimulant Task Force of the American Academy of Sleep Medicine. Sleep 2005; 28(9): 1144–68.
[43] DavenportN. Unpublished data, Naval Safety Center, Norfolk, VA. 2010.
[44] SchultzD, MillerJC. Fatigue and use of Go/No-Go pills in extraordinarily long combat sorties. Aviat Space Environ Med 2004; 75: 370–1.
[45] BongioanniC. Sedative found in blood of pilot in Philippines copter crash. Pacific Stars and Stripes 6 Nov 2003.
[46] Cold Medicine a Contributing Factor: Nimitz Crash Blamed on Pilot Error. Associated Press: The Washington Post Tuesday August 10 1982, p. A–4.
[47] AhmetS, AhmetA, CraftKJ, CanfieldDV, ChaturvediAK. First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990–2005. Aviat Space Environ Med 2007; 78: 514–22.
[48] Coalition Investigation Board (CIB) Report, Tarnak Farms, Afghanistan 04/17/02. http://www.globalsecurity.org/military/library/report/2002/tarnak_farms_report.doc (Accessed 11 Jun 2010).
[49] Board of Inquiry – Tarnak Farm 2002. National Defense and the Canadian Forces. http://www.globalsecurity.org/military/library/report/2002/tarmak_content_e.htm. (Accessed 11 Jun 2010).
[50] FriscolantiM. Friendly Fire: The Untold Story of the U. S. Bombing that Killed Four Canadian Soldiers in Afghanistan. Toronto: John Wiley & Sons; 2005.
[51] FriscolantiM. p. 534.
[52] FriscolantiM. p. 432.
[53] FriscolantiM. p. 448.
[54] ABC News Archive. Need for Speed: Did Amphetamines Play a Role in Afghanistan Friendly Fire Incident? Dec 20 2002. http://www.acftv.com/news/article.asp?news_id=61. (Accessed 4 Sept 2010).
[55] CNN Transcripts. Shepperd: ‘Go-pills’ Common for Pilots. Jan 3 2003. http://www.cnn.com/2003/US/01/03/cnna.shepperd/index.html?iref=allsearch (Accessed 4 Sept 2010).
[56] RussoMB. Recommendations for the ethical use of pharmacologic fatigue countermeasures in the U.S. military. Aviat Space Environ Med 2007; 78(5 Suppl.): B119–27.
[57] RussoMB, ArnettMV, ThomasML, CaldwellJA. Ethical use of cogniceuticals in the militaries of democratic countries. Am J Bioethics 2008; 8(2): 39–49.
[58] LeducP, RoweT, MartinC, CurryI, et al. Performance Sustainment of Two Man Crews During 87 Hours of Extended Wakefulness with Stimulants and Napping. USAARL Report No. 2009–04. Feb 2009.
[59] HoweEG. Mixed Agency in Military Medicine: Ethical Roles in Conflict. Military Medical Ethics, Vol. 1. Department of Defense, Office of The Surgeon General, US Army, Borden Institute. 2003: Chapter 12.
[60] SchermerM, BoltI, de JonghR, OlivierB. The future of psychopharmacological enhancements: expectations and policies. Neuroethics 2009; 2: 75–87.

References

[7] CzeislerCA, DuffyJF, ShanahanTL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 1999; 284: 2177–81.
[8] Van DongenH. Comparison of mathematical model predictions to experimental data of fatigue and performance. Aviat Space Environ Med 2004; 75(3 Suppl): A15–36.
[9] MallisMM, MejdalS, NguyenTT, DingesDF. Summary of the key features of seven biomathematical models of human fatigue and performance. Aviat Space Environ Med 2004; 75(3 Suppl): A4–14.
[10] Dean DA 2nd, FletcherA, HurshSR, KlermanEB. Developing mathematical models of neurobehavioral performance for the “real world”. J Biol Rhythms 2007; 22(3): 246–58.
[11] DingesDF. Critical research issues in development of biomathematical models of fatigue and performance. Aviat Space Environ Med 2004;75(3Suppl): A181–91.
[12] FriedlKE, MallisMM, AhlersST, PopkinSM, LarkinW. Research requirements for operational decision-making using models of fatigue and performance. Aviat Space Environ Med. 2004; 75(3 Suppl): A192–9.
[13] BorbelyAA, AchermannP. Concepts and models of sleep regulation: an overview. J Sleep Res 1992; 1(2): 63–79.
[14] AkerstedtT, FolkardS. The three-process model of alertness and its extension to performance, sleep latency, and sleep length. Chronobiol Int 1997; 14(2): 115–23.
[15] HurshSR, RedmondDP, JohnsonML, et al. Fatigue models for applied research in warfighting. Aviat Space Environ Med 2004; 75(3 Suppl): A44–53.
[16] BelenkyG, WesenstenNJ, ThorneDR, et al. Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: a sleep dose-response study. J Sleep Res 2003; 12(1): 1–12.
[17] Van DongenHP, MaislinG, MullingtonJM, DingesDF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003; 26(2): 117–26.
[18] JohnsonML, BelenkyG, RedmondDP, et al. Modulating the homeostatic process to predict performance during chronic sleep restriction. Aviat Space Environ Med 2004; 75(3 Suppl): A141–6.
[19] McCauleyP, KalachevLV, SmithAD, et al. A new mathematical model for the homeostatic effects of sleep loss on neurobehavioral performance. J Theor Biol 2009; 256(2): 227–39.
[20] RuppTL, WesenstenNJ, BliesePD, BalkinTJ. Banking sleep: realization of benefits during subsequent sleep restriction and recovery. Sleep 2009; 32(3): 311–21.
[25] National Transportation Safety Board. Uncontrolled Collision with Terrain American International Airways Flight 808, Douglas DC-8-61, N814CK. NTSB Report #AAR-94-04, NTIS #PB94-910406.
[27] Van DongenHP, MottCG, HuangJK, et al. Optimization of biomathematical model predictions for cognitive performance impairment in individuals: accounting for unknown traits and uncertain states in homeostatic and circadian processes. Sleep 2007; 30(9): 1129–43.
[28] RajaramanS, GribokAV, WesenstenNJ, BalkinTJ, ReifmanJ. Individualized performance prediction of sleep-deprived individuals with the two-process model. J Appl Physiol 2008; 104(2): 459–68.
[29] RajaramanS, GribokAV, WesenstenNJ, BalkinTJ, ReifmanJ. An improved methodology for individualized performance prediction of sleep-deprived individuals with the two-process model. Sleep 2009; 32(10): 1377–92.
[30] BalkinTJ, KamimoriGH, RedmondDP, et al. On the importance of countermeasures in sleep and performance models. Aviat Space Environ Med 2004; 75(3 Suppl): A155–7.
[31] Benitez BenitezPL, KamimoriGH, BalkinTJ, GreeneA, JohnsonML. Modeling fatigue over sleep deprivation, circadian rhythm, and caffeine with a minimal performance inhibitor model. Methods Enzymol 2009; 454: 405–21.
[32] PuckeridgeM, FulcherBD, PhillipsAJ, RobinsonPA. Incorporation of caffeine into a quantitative model of fatigue and sleep. J Theor Biol 2011; 273(1): 44–54.
[33] BalkinTJ, BadiaP. Relationship between sleep inertia and sleepiness: cumulative effects of four nights of sleep disruption/restriction on performance following abrupt nocturnal awakenings. Biol Psychol 1988; 27(3): 245–58.
[34] TassiP, MuzetA. Sleep inertia. Sleep Medicine Reviews 2000; 4(4): 341–53.